PTRG-DES Consortium

Gyeongsang National University Hospital13,160 enrolled

Overview

The PTRG-DES consortium is a coalition composed of multi-center, real-world registries including CAD patients treated with DES in South Korea. From 9 academic registries in Korea, a total of 13,160 patients were enrolled for this database between July 2003 and August 2018. The aim of the study was to investigate long-term prognostic implications of platelet function and genotypes after DES implantation for significant CAD in South Korea.

The investigators enrolled patients treated with DES during DAPT including clopidogrel who had at least one of VerifyNow test (PRU and ARU) and genotyping. In this consortium, the investigators tried to find the unique characteristics of East Asians based on platelet function, genotype and inflammatory markers.

Study Type

OBSERVATIONAL

Enrollment

13,160

Conditions

Coronary Artery Disease Clopidogrel, Poor Metabolism of Platelet Dysfunction Stent Thrombosis

Interventions

Clopidogrel TabletsDRUG

DES-treated patients were treated with clopidogrel 75 mg daily and aspirin 100 mg daily

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Consecutive patients at every centre successfully treated with one or more DES approved by the US FDA or CE mark and who were adequately loaded with clopidogrel were eligible for enrolment, regardless of patient or lesion complexity. Exclusion Criteria: * the occurrence of a major complication during the procedure or before platelet function testing, or if bypass surgery was planned after PCI. * Any P2Y12 inhibitor other than clopidogrel * PCI strategy other than DES * Needed oral anticoagulant (e.g. atrial fibrillation)

Locations (1)

Gyeongsang National University Changwon Hospital

Changwon, Gyeongsangnam-do, South Korea

Outcomes

Primary Outcomes

MACCE

All-cause death, MI, stroke or stent thrombosis

Time frame: upto 10 years

Secondary Outcomes

Major bleeding

BARC type 3-5 bleeding

Time frame: upto 10 years

MACE1

CV death, MI and stent thrombosis

Time frame: upto 10 years

MACE2

CV death, MI, stent thrombosis and revascularization

Time frame: upto 10 years

Each clinical event

all-cause death, CV death, MI, stroke, stent thrombosis, revascularization or major bleeding

Time frame: upto 10 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.